Pharma must assess real-world evidence to keep up with shifts in market access landscape; Report

As the overall costs of drugs continue to increase and pricing pressures shift the dynamics of the healthcare market, pharmaceutical companies must analyze real-world trends in different treatment spaces, and assess existing and expected levels of competition, in order to gain optimal market access, says business intelligence provider.

According to GBI Research’s latest CBR Pharma report, this kind of analysis, known as Health Economics and Outcome Research (HEOR), is an important element of market access which encompasses aspects such as real-world data, quality of life, budget impact, and cost-effectiveness, along with clinical efficiency.

Rodrigo Gutierrez Gamboa, managing analyst for GBI Research, states: “Traditionally, once a drug was registered in a country, it was automatically reimbursed and available for an eligible population of patients. Today, however, regulatory approval does not guarantee market access, as the cost-effectiveness of any given drug must be thoroughly demonstrated before it receives coverage in a health system.”